Author: camel

- Annual sales of HuaTangNing exceeded 4 million packs, a year-on-year increase of 91%, with revenues reaching RMB 492.9 million, a year-on-year increase of 93%, marking outstanding results from the Company’s fully independent commercialization operation.- Delivered record financial performance, with profit before tax reaching RMB 1,106.4 million; maintained a robust bank balance and cash position of RMB 1,092.3 million at year-end, laying a solid foundation for sustainable operations and growth.- Gross margins rose to 56.9%, and selling expenses as a percentage of revenue were optimized to 33.6% from 59.9%, significantly enhancing profitability.- HuaTangNing renewed its listing in the new National Reimbursement Drug List (NRDL) at the same price in 2025 for the calendar years 2026 and 2027, reaffirming its clinical and innovative value.- With the approval of PTE, market exclusivity in China granted another 5 years to April 2034, further strengthening commercial certainty.- Dorzagliatin was approved for commercialization in Hong Kong as HYHOMSIS®, accelerating its global expansion toward South-East Asia.- Multiple real-world evidence published to demonstrate therapeutic advantage of dorzagliatin.- Continuous expansion of therapeutic potential of glucose homeostasis and initiation of new first-in-disease indications study covering diabetes prevention, rare diseases, mild cognition impairment and frailty.SHANGHAI, Mar 27, 2026 - (ACN Newswire via SeaPRwire.com) – Hua Medicine ("the Company", Hong Kong Stock Exchange Stock Code: 2552) announces the audited consolidated results of the Company and its subsidiaries for the year ended December 31, 2025 (the “Reporting Period”). During the Reporting Period, the commercialization of HuaTangNing (dorzagliatin tablets), the Company’s core product – the global first-in-class innovative anti-diabetes medicine, glucokinase activator (GKA) – advanced comprehensively across all fronts, the Company’s independent commercialization team was efficiently and seamlessly established in its first year of operations, the Company’s R&D pipeline continued to be enriched, and the Company’s financial performance achieved a historic breakthrough, successfully entering a new stage of profitability, injecting strong momentum into the innovative development of the global diabetes treatment field.Dr. Li CHEN, Founder and CEO of Hua Medicine, stated: “2025 is a remarkable year in the commercialization operation of Hua Medicine. The Company has successfully advanced from R&D to commercialization driven organization and achieved the fully independent capacity in commercialization of global first in class novel glucose homeostasis regulator HuaTangNing. With strong market execution and product competitiveness, we have achieved nearly triple-digit growth in sales volume and revenue over 2024 when the commercialization was farmed out to sales and marketing partners. At the same time, the Company has made key progress in global market expansion through registration of drozagliatin in Hong Kong and position it toward 700 M population in south-east Asia. We continue to expand the clinical application of glucose homeostasis regulation technology and engage in new indications such as early-stage Alzheimer’s disease and Frailty. The first-in-disease efforts in GCK-MODY and Frailty set the new innovation course of Hua Medicine in the next 5 years.” Business Highlights and Operational Progress- Fully Powered Commercialization, Historic Breakthrough in ProfitabilityOn January 1, 2025, the Company assumed full responsibility for the commercialization of HuaTangNing, allowing the company to consolidate both operational and strategic control over market execution in China. The Company successfully built a professional sales team covering 10 sales regions around the country, focusing on marketing, medical affairs and commercial operation. Through an AI-empowered digital commercialization platform, operational efficiency and sales productivity were greatly enhanced, injecting new vitality into the Company’s commercial development.Reimbursement coverage under the NRDL has significantly increased accessibility, especially in Tier 2 and Tier 3 hospitals, and played a critical role in accelerating patient adoption. Since its launch in October 2022, HuaTangNing has been prescribed to over 500,000 patients through 3,000+ hospitals, community centers, pharmacies and online channels.Sales performance exceeded expectations, with 4.011 million packs of HuaTangNing sold during the reporting period, representing a 91% increase over the fiscal year 2024. This growth was achieved at the same price for both periods, underscoring strong demand and successful execution of Hua’s commercial strategy.In terms of profitability, the Company’s gross profit reached approximately RMB280.4 million, a year-on-year increase of 125%. Thanks to expanded production scale and optimized manufacturing processes, the Company’s gross margin improved to 56.9%, increasing by 8.2 percentage points as compared to 48.7% for the year of 2024. Selling expenses increased only by RMB12.3 million to RMB165.5 million, reflecting a significant positive trend towards profitability when our selling expenses in the 2025 fiscal year represents only 33.6% of revenue, whereas in the 2024 fiscal year, our selling expenses represented approximately 59.9% of revenue. In fiscal year 2025, our commercialization efforts achieved profits of approximately RMB114.9 million (as defined by gross profits less selling expenses). Although we expect to continue to increase personnel to our commercialization team, we expect this profitability trend in our commercial operations in mainland China to continue.Following the termination of the collaboration with Bayer at the end of 2024, dorzagliatin achieved a record-high sales volume. Profit before tax increased to RMB1,106.4 million for the fiscal year 2025. We ended fiscal year 2025 with a cash position of approximately RMB1,092.3 million.- Accelerated Global Layout, Strengthened Core Rights and InterestsThe Company took a key step in global expansion. On February 27, 2026, dorzagliatin (trade name: MYHOMSIS®, was successfully approved for marketing by the Hong Kong regulatory authority. The Company plans to officially launch the product in the Hong Kong market by the middle of 2026 and further expand to Asian regions. In addition, the Company submitted a new drug registration application in Macau in 2025.The Company also made new progress in intellectual property protection. In February 2026, the patent term extension (PTE) application for dorzagliatin was formally approved by the China National Intellectual Property Administration, thereby the core patent protection period of dorzagliatin extended to April 2034 and an additional 5-year market exclusivity obtained, which provides a strong guarantee for the product’s long-term market competition.In 2025, dorzagliatin was recognized as national innovation and an effective therapy for chronic diseases by the regulatory authorities in China. Accordingly, the same NRDL price was offered for the calendar years 2026 and 2027. Reimbursement coverage under the NRDL has significantly increased accessibility, especially in Tier 2 and Tier 3 hospitals, and played a critical role in accelerating patient adoption. The Company will continue to safeguard the product’s market competitiveness and patient accessibility and accelerate the popularization of the drug among patients.- Advancement of Real-World Studies, Continuous Validation of Clinical ValueReal-world evidence (RWE) studies continue to corroborate the key role of dorzagliatin in improving glucose-dependent pancreatic islet secretion function, and demonstrate its efficacy in diabetes prevention, remission, and delaying or preventing diabetes complications.The RWE study sponsored by Hua Medicine HMM0701 with 380 T2D patients was fully enrolled in 2025. The interim analysis, as reported at the 2025 American Diabetes Association (ADA), showed that 86% of such patients were taking two or more antidiabetic drugs and 41% of such patients were using insulin. After a 6-month treatment, a significant improvement of glycemic control was observed with HbA1c reduction from 8.1% to 7.3% with the mean time-in-range (TIR) levels increasing to over 70%. Thus far, the studies have demonstrated that when dorzagliatin is administered in combination with other antidiabetic drugs, such patients have experienced significantly improved post-meal glucose levels and improved β-cell function.Separately, a mechanistic study with dorzagliatin (employing double-tracer measurement) was conducted in the United States to provide scientific evidence of hepatic glycogen formation in T2D patients with an average of 17 years of diagnosed diabetes. In this study, patients were treated with dorzagliatin twice daily for 6 weeks. The results showed that dorzagliatin increased direct glucose flux to hepatic glycogen implying the improvement of restoration of hepatic Glucokinase (GK) function. Together with the clinical research data that dorzagliatin improves early phase insulin release and GLP-1 secretion, recovery of hepatic glycogen synthesis in T2D patients offers an important path in controlling post-meal glucose excursion and provides a unique opportunity in controlling diabetes complications, such as diabetes kidney diseases and mild cognition impairment.The RWE sponsored by Hua Medicine (HMM0601) has completed clinical trials with over 2,000 subjects, with average diabetes duration of 7.9 years and above 30% having disease duration more than 10 years. The initial results suggest that dorzagliatin is safe and well tolerated in Chinese T2DM patients. There were no new adverse effects observed in the study and the incident rate remains as low as what was observed in Phase III clinical trials. Patient adherence was generally high, with a mean adherence rate of approximately 95%. In this study, 80% of the participants have used one or more oral anti-diabetes medicine, and 20% used insulin. Dorzagliatin demonstrated good efficacy and safety not only in the overall population but also in elderly, obese, and hyperglycemic patient populations, whether used as monotherapy or in combination with metformin, SGLT2 inhibitors, insulin, and other medications. The topline results will be reported at the 2026 American Diabetes Association.- Deepened Clinical R&D, Continuous Expansion of New IndicationsNew Indication for Dorzagliatin – MODY-2 Patients.Medical experts in mainland China and Hong Kong have conducted independent clinical and preclinical studies of dorzagliatin for MODY-2 treatment. MODY-2, also called GCK-MODY, is a monogenic disease in which patients have a genetic defect of glucokinase gene (GCK) which results in elevated blood glucose and significant reduction of the second phase insulin secretion. The population of GCK-MODY patients is approximately 1.7 million in China. These patients are diagnosed with diabetes at a young age and represent an unmet medical need given that currently available medications are not effective. In clinical studies with MODY-2 patients, China investigators have reported that dorzagliatin is effective in reducing blood glucose levels to normal levels in MODY-2 patients who previously failed to manage their elevated blood glucose levels when treated with metformin, TZD, DPP-IV inhibitors, and SGLT-2 inhibitors. Additional results demonstrated that a single dose of dorzagliatin improved overall glucose sensitivity and second phase insulin secretion significantly in GCK-MODY patients, suggesting a unique mechanism of action of dorzagliatin to regulate GLP-1 secretion. Based on such results, Hua Medicine has communicated and reached a consensus with the CDE at NMPA to file the IND submission of dorzagliatin for MODY-2 patients in 2026.Dorzagliatin for Diabetes Prevention.Prevention of diabetes is an important focus at Hua Medicine. There are approximately 1.12 billion people living with prediabetes worldwide. We have initiated SENSITIZE 3 clinical study in Hong Kong in pre-diabetic (IGT) subjects and in early diabetes patients. These studies represent first-in-disease studies. In this double-blinded placebo-controlled study, we will evaluate the blood glucose management and pancreatic function under IVGTT and OGTT conditions to better define the clinical treatment baseline and endpoints. We expect to complete this study in 2026 and explore the opportunity to file IND applications of dorzagliatin for diabetes prevention in China and Asian Pacific regions thereafter. Dorzagliatin for Neurodegenerative Diseases.MCI shows approximately 15.5% prevalence among elderly people in China and approximately 22% in the US, and is common in T2D patients with a 45% incidence rate. The development of dorzagliatin for neurodegenerative disease is a new focus in our drug discovery efforts. Through the Genome-Wide Association Study (GWAS) and Mendelian Randomization (MR) study, we have realized the important role of GCK gene activation in the prevention of memory loss and cognitive impairment in humans. It has also come to our attention that post-meal glucose excursion is closely related to Alzheimer disease and dementia. The bio-energy balance in the brain is largely dependent on the glucose homeostasis control in the peripheral organ and the neural network communication in the central and peripheral system via spatial temporal management. Impaired glucose homeostasis and diabetes conditions result in a reduction of glucose transporter expression and insulin receptor expression in the brain, which can be prevented by low dose dorzagliatin. We have realized the potential of dorzagliatin in the treatment of mild cognitive impairment (MCI) and will initiate these first-in-disease clinical studies in the future.Dorzagliatin for Frailty.Frailty is an age-related geriatric syndrome characterized by reduced tolerance to internal and external stressors. Approximately 17% of Americans and 11% of Asians over the age of 50 suffer from frailty, while pre-frailty affects roughly 50% and 47% of these populations, respectively. It is not a single-organ disease, but the consequence of dysregulated multisystem homeostasis. Genetic evidence supports the causal effects of glucokinase (GK) activation on lowering frailty risk. We plan to initiate clinical studies in the future to advance dorzagliatin’s application in frailty.Development of combination therapy for diabetes and complications.Dorzagliatin rescues pancreatic function in glucose insulin secretion and GLP-1 secretion, as evidenced by clinical and basic research results. It also improves hepatic insulin sensitivity and reduces hepatic insulin resistance through recovery of hepatic glycogen synthesis in T2D patients. The combination of dorzagliatin with DPP-IV inhibitors, SGLT-2 inhibitors, and GLP-1 agonists have demonstrated effective regulation of lipid metabolism. Studies in combination with anticancer PI3K inhibitors have also offered unique benefits for glucose homeostasis management.- Diversified Product Pipeline, Innovative Layout for Future GrowthHua Medicine continues to enrich its pipeline layout based on core products. The Company has accelerated the R&D of a fixed-dose combination (FDC) of dorzagliatin and metformin as a twice-daily therapy for Type 2 diabetes patients with inadequate glycemic control on metformin alone, to further improve patient medication compliance. The product is supported by the strong results of the loose-dose combination in both Phase III clinical trials and real-world use. The Company has submitted an IND application to NMPA, and the GMP commercial manufacturing process has been successfully carried out, preparing for the pivotal bioequivalence study for NDA filing in 2027. Clinical studies have shown that the combination of dorzagliatin and metformin can better control blood glucose, reduce postprandial blood glucose and improve fasting blood glucose, providing new clinical value for optimizing blood glucose homeostasis endpoints.We have advanced our 2nd generation GKA as a once daily therapy for patients with obesity, leveraging dorzagliatin effects in improved glucose-stimulated GLP-1 secretion in the pancreas and in the intestine. The MAD study of the 2nd generation GKA was initiated in the United States with first-patient-in in December 2025, and we expect to report topline data by the middle of 2026.Meanwhile, the Company is also exploring combination therapy regimens of dorzagliatin with GLP-1 receptor agonists, SGLT-2 inhibitors and other drugs. In a recently published clinical trial in China, researchers reported the superior benefits of our dorzagliatin in combination with semaglutide as compared to semaglutide alone in a 12-week study. The combination group showed superior results across several key measures, including glycemic control, bodyweight related indicators and β-cell function.Financial Summary- Revenue generated by the Company was approximately RMB 492.9 million from the sale of approximately 4.011 million packs of HuaTangNing, increases of approximately 93% and 91% respectively, as compared with the year ended December 31, 2024.- Gross profit generated by the Company for the year ended December 31, 2025, was approximately RMB280.4 million, representing an increase of approximately 125%, as compared with the year ended December 31, 2024, and gross margins rose to 56.9%.- Profit before tax increased by approximately 542% to approximately RMB1,106.4 million for the year ended December 31, 2025, as compared with the year ended December 31, 2024.- Bank balances and cash position was approximately RMB1,092.3 million as of December 31, 2025.- Expenditures incurred by the Company for the year ended December 31, 2025, were approximately RMB433.4 million.Forward-Looking StatementsThis document contains statements regarding Hua Medicine's and its products' future expectations, plans and prospects. Such forward-looking statements relate only to events or information as of the date on which the statements are made in this document and are subject to change in light of future developments. Except as required by law, the Company shall not be obligated to update or publicly revise any forward-looking statements or unforeseen events after the date of such statements, whether as a result of new information, future events or other circumstances. Please read this document carefully and understand that actual future performance or results of the Company may differ materially from expectations due to various risks, uncertainties or other statutory requirements.About Hua MedicineHua Medicine (The “Company”) is an innovative drug development and commercialization company based in Shanghai, China, with companies in the United States and Hong Kong. Hua Medicine focuses on developing novel therapies for patients with unmet medical needs worldwide. Based on global resources, Hua Medicine teams up with global high-calibre people to develop breakthrough technologies and products, which contribute to innovation in diabetes care. Hua Medicine's cornerstone product HuaTangNing (dorzagliatin tablets), targets the glucose sensor glucokinase, restores glucose sensitivity in T2D patients, and stabilizes imbalances in blood glucose levels in patients. HuaTangNing was approved by the National Medical Products Administration (NMPA) of China on September 30th, 2022. It can be used alone or in combination with metformin for adult T2D patients. For patients with chronic kidney disease (CKD), no dose adjustment is required. It is an oral hypoglycemic drug that can be used for patients with Type 2 diabetes with renal function impairment. In February 2026, dorzagliatin (Trade name: MYHOMSIS®,) was approved for marketing by the Pharmaceutical Services of the Department of Health of the Government of the Hong Kong Special Administrative Region of China.For more informationHua MedicineWebsite: www.huamedicine.comInvestorsEmail: ir@huamedicine.comMediaEmail: pr@huamedicine.com Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Mar 26, 2026 - (ACN Newswire via SeaPRwire.com) – CALB (03931.HK) rolled its pioneering 'R46 cylindrical battery' system off the production line at the Chengdu factory on March 25, an aviation power battery set to power the XPENG ARIDGE X3-F Land Aircraft Carrier flying car. The recently unveiled R46 cylindrical battery technology boasts an energy density of 360 Wh/kg, the highest-density solid-liquid hybrid cylindrical battery in the industry. It achieves an exceptional balance between high safety, high power density and high energy density, meets aviation-grade safety standards, and will be equipped in several of ARIDGE's flying car models.The partnership between the two parties began in 2022, with CALB assisting ARIDGE in completing the world’s maiden flight of an electric vertical take-off and landing (eVTOL) flying car. Following rigorous validation, the reliability of CALB’s battery product has been fully verified. Building on this momentum, CALB assembled a team of top researchers to focus on the next-generation advanced R46 cylindrical battery system, tasked with addressing a range of scientific and technological challenges.Taking the lead in collaborating with leading institutions including ARIDGE, CALB has been awarded support by the National Key R&D Program Project, further positioning the technologies at the forefront of global innovation in intrinsic safety and high-specific-energy aviation power batteries. Consequently, the two parties signed a deepened strategic cooperation agreement in April 2025, establishing an exclusive supply relationship for next-generation models.From leading the National Key R&D Program focused on advanced R46 cylindrical battery system technology to achieving the mass production of flying car batteries, CALB is accelerating its expansion into forward-looking emerging sectors. The company's commercialization capability across diversified application scenarios continues to strengthen, opening new growth opportunities in the competition for next-generation energy technologies. CALB Group Co., Ltd. https://en.calb-tech.com/ [03931.HK] Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Mar 27, 2026 - (ACN Newswire via SeaPRwire.com) – 26 March, Unisound (09678.HK) announced its audited annual results for the year ended December 31, 2025. As the Company's first annual results announcement since listing, it underscores strong growth momentum and continued improvement in its financial profile.Revenue Mix Continues to Improve, with Faster Growth in H2For the full year of 2025, Unisound achieved total revenue of $175 million, representing a year-on-year (YoY) increase of 29%. Revenue in the second half of the year increased by 33% YoY to $117 million.It is worth noting that the Company's large language model (LLM) business generated a full-year revenue of $88.43 million, surging by over 10 times YoY. In particular, this business contributed approximately $72.49 million in H2 revenue, five times the level recorded in H1, demonstrating a compelling capacity for large-scale commercial application.Losses Narrowed Significantly, Making the Path to Profitability Increasingly ClearAlongside the rapid revenue growth, the Company's losses improved markedly. In the second half of 2025, the Company's net loss narrowed by 84% YoY, and its adjusted loss narrowed by 92% YoY, approaching break-even. This reflects the Company's ongoing improvements in cost control and operational efficiency.Simultaneously, some of the Company's operating metrics saw marked improvement. The adjusted expense ratio declined significantly by 10 percentage points YoY, while selling expenses decreased rather than increased and accounted for only 5.4%, highlighting a clear improvement in cost-to-efficiency ratio. In 2025, revenue per employee reached $365,300, up 25% YoY from $292,900 in 2024. Employee productivity continued to lead the industry, clearly underscoring the Company's core strengths in technology-driven, lean operations.Dual-Engine Strategy Gains Traction, with AI in Healthcare and AI in Daily Life Advancing in TandemIn 2025, driven by both technological breakthroughs and policy tailwinds, global demand for AI continued to rise. Unisound adhered to its "Strong Foundation Model + Deep Application" strategy, continued to strengthen its multimodal technology foundation, and drove the continuous elevation of the global influence of its proprietary large model matrix in fields such as healthcare, speech, and OCR.On the commercialization front, the Company leveraged its AI-native organization to accelerate business execution, and its dual-engine strategy in AI in Healthcare and AI in Daily Life delivered notable results. During the reporting period:The AI in Daily Life business achieved revenue of $140 million, a YoY increase of 30.8%. Among this, the Transportation segment recorded nearly 40% YoY growth. At present, AI agent applications based on the Shanhai large model have been deployed in more than 10 cities, including Qingdao, Ningbo, Shenzhen and Nanning. In addition, cumulative AI chip shipments exceeded 110 million units, further validating the Company's scale capabilities in endpoint AI products.The AI in Healthcare business achieved revenue of $35.38 million, a YoY increase of 22.3%, with average revenue per customer growing by 53.2% YoY. In 2025, over 70% of the hospitals the Company collaborated with were tertiary hospitals, and more than one-third of customers had maintained continuous cooperation for over three years. The medical-record entry and generation products powered by the medical large model delivered a 10-fold YoY increase in full-annual medical record generation at a single campus of a leading Class III hospital. The commercial insurance AI agent platform recorded a 37-fold YoY increase in case processing volume. In deep cooperation with a leading insurance group, the expense control rate was effectively raised to approximately 20%, delivering more than $145 million in incremental cost management compared with traditional review methods, comprehensively empowering insurance institutions to refine their medical risk management operations.Continued R&D Investment Strengthens the Technology MoatTo consolidate its industry-leading position, the Company continued to invest heavily in R&D in 2025. Full-year R&D expenses exceeded $55.09 million, accounting for 75% of the Company's adjusted operating expenses, while R&D personnel accounted for 69% of the total workforce. This sustained investment drove breakthroughs across multiple technology areas. For example, in the MedBench 4.0 evaluation, the Company ranked first place in three technical paradigms: "Medical AI Agent," "Medical Large Language Model," and "Medical Multimodal Large Model," earning a "Triple Crown."Outlook: Deepening the Technological Foundation and Expanding Application BoundariesLooking ahead, Unisound will continue to deepen its "Strong Foundation Model + Deep Application" strategy. On the technological front, the Company will continue to increase strategic investment in foundational large models and strive to maintain a world-class level. On the application front, it will use the large-scale expansion of MaaS (Model-as-a-Service) and AI agents as its core growth engine, driving exponential growth in its AI in Daily Life and AI in Healthcare businesses. Meanwhile, the Company is actively exploring the establishment of a recurring revenue system through models such as API calls and Token-based billing, and regards opportunities in consumer-facing (C-end) products as a second growth curve to further expand its commercialization boundaries.Between Q2 and Q3 2026, Unisound will launch a native AI agent large model for programming and office applications, which is expected to double both intelligence density and token production efficiency. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Financial HighlightsRMB 100 millionFor the 12 months ended 31 DecemberChange (%)20252024Revenue1566.111,776.64-11.85% Profit28.4265.53-56.64% Profit before Tax28.1665.95-57.30% Gross Profit194.95222.47-12.37% Gross Profit Margin12.45%12.52%-0.07pct Net Profit13.3741.95-68.12% Net Profit Attributable to Shareholders and Other Equity Holders2.2129.72-92.57% Net cash flows from operating activities 185.1492.6499.86% Dividend per share (RMB/share, tax inclusive)RMB 0.179RMB 0.176N/A Total dividend payout9.399.45-0.60% Performance Highlights1. Solid operating core segments with resilient high-quality development: In 2025, the Group achieved revenue of RMB 156.611 billion, net profit of RMB 1.337 billion, and maintained a gross profit margin of 12.45%, with a balanced domestic and overseas revenue structure.2. Dual improvement in cash flow and financial quality, with significantly enhanced risk resilience: Net cash flows from operating activities increased substantially by 99.86% to RMB 18.514 billion, while the cash and cash equivalents as of the end of the Year reached RMB 24.3 billion; the scale of interest-bearing debt decreased by RMB 4.7 billion year-on-year (“YoY”) to RMB 34.4 billion, and net interest expenses decreased by approximately RMB 730 million YoY, with the financial structure continuing to be optimized.3. Cash dividends and share buybacks implemented in parallel to reward investors: The Group proposes a cash dividend of RMB 0.179 per share (tax inclusive) for 2025. Together with multiple rounds of H-share and A-share buyback plans launched during the Year, the total proposed dividend and completed buybacks for 2025 amounted to RMB 1.852 billion.4. Significant improvement in profitability of energy-related businesses, becoming a key growth driver of the Group: Net profit of the offshore engineering segment and the financial and asset management segment (primarily drilling platform leasing) increased by approximately RMB 1.212 billion in total, while the energy, chemical and liquid food equipment segment increased by RMB 308 million. Among them, the gross profit margin of the offshore engineering segment increased significantly by 5.72 percentage points to 14.83%. Orders on hand for offshore engineering and energy, chemical and liquid food equipment reached US$5.09 billion and RMB 29.75 billion, respectively, with certain shipyards’ production schedules extending to 2030.5. Logistics-related businesses continued to serve as the Group’s “ballast stone”: During the Year, businesses such as container manufacturing and road transportation vehicles were affected by exchange rate fluctuations and cyclical changes, resulting in pressure on gross profit margins and profitability. However, the core segments remained solid, and the Group’s competitive advantages in the industry continued to be consolidated. Core products such as standard dry containers, reefer containers, tank containers and semi-trailers have maintained the world’s No.1 position for many consecutive years.6. Breakthroughs in both technology and orders in key businesses, with competitiveness highly recognised: In the high-end offshore engineering equipment sector, CIMC Raffles successfully developed the most complex products in the offshore industry, including FPSO/FLNG, becoming the only enterprise in China with dual-project EPCI general contracting capabilities; in the modular data center sector, the Group providing technical and manufacturing delivery services of prefabrication data center to industry customers exceeding 300MW, leading new transformation in computing power infrastructure.HONG KONG, Mar 26, 2026 - (ACN Newswire via SeaPRwire.com) – China International Marine Containers (Group) Co., Ltd. (“CIMC Group” or the “Group”, stock code: 000039.SZ/02039.HK) is pleased to announce the audited annual results for the 12 months ended 31 December 2025 (the “Year”).The Group’s management stated, “In 2025, profound global changes unseen in a century accelerated, and the global economy demonstrated resilience amid volatility. Positioned in an era of both opportunities and challenges, the Group closely adhered to the strategic theme of “accelerating the construction of new growth drivers and focusing on promoting high-quality development”. While stabilising its operating fundamentals, the Group further deepened its forward-looking strategic layout in the energy business and achieved fruitful results. For the year of 2025, the Group recorded revenue of RMB 156.61 billion and net profit of RMB 1.34 billion. Cash flows from operating activities increased significantly by 99.9% to RMB 18.51 billion, with the asset structure continuously optimized and risk resilience further enhanced.”In particular, to sincerely reward investors, CIMC Group proposes to distribute a cash dividend of RMB 0.179 per share (tax inclusive) to all shareholders for 2025, amounting to a total proposed cash dividend of RMB 939 million (tax inclusive). Meanwhile, the Group implemented share buybacks totalling RMB 913 million during 2025, bringing the combined total to RMB 1.852 billion.Segments Results (RMB 100 million)2025 Business indicatorsRevenueAs % of the total revenueGross profitAs % of the gross profitGross profit marginNet profitContainer manufacturing430.0927.46%57.5529.52%13.38%18.82Road transportationvehicles201.7812.88%32.0616.45%15.89%9.27Energy, chemical, and liquid food equipment271.9217.36%40.2420.64%14.80%10.40Offshore engineering179.3811.45%26.6013.65%14.83%10.57Logistics services267.9317.11%16.708.57%6.23%3.64Airport facilities and logistics equipment/fire safety and rescue equipment76.194.86%15.147.76%19.87%2.64Total of major segments1427.2991.12%188.2996.59%13.19%55.34Core Business Performance1. In logistics field:In the container manufacturing business, during the Year, despite negative supply chain factors such as U.S. tariff policies and geopolitical conflicts, global merchandise trade demonstrated strong resilience. Intra-regional trade, Asia-Europe routes and emerging market routes became the main drivers of incremental growth. Meanwhile, factors such as detours around the Red Sea, port congestion, environmental requirements in shipping and increasing complexity of trade routes reduced transportation efficiency, structurally boosting underlying demand and pushing the global container fleet into a new structural phase. As a result, overall demand for new containers in 2025 remained at a relatively high level, exceeding the average of the past decade. During the Year, the production and sales volume of the Group’s container manufacturing business declined YoY, in line with overall industry expectations, but the Group maintained its global No.1 position. Accumulated sales volume of dry cargo containers reached 2,224,900 TEUs (2024: 3,433,600 TEUs), representing a YoY decrease of 35.2%. Accumulated sales volume of reefer containers reached 208,200 TEUs (same period last year: 138,600 TEUs), representing a YoY increase of 50.2%. During the Year, the container manufacturing segment recorded revenue of RMB 43.009 billion, net profit of RMB 1.882 billion, and a slight decline in gross profit margin to 13.38%.In the logistics services business, during the Year, the segment recorded revenue of RMB 26.793 billion, representing a YoY decrease of 14.64%, and net profit of RMB 364 million, representing a YoY decrease of 16.65%, in line with industry trends. CIMC Wetrans actively adjusted its business structure and integrated resources. During the Year, self-sourced cargo volume increased by 6% YoY, while second-hand container trading and warehousing distribution in port logistics reached record highs. The industry logistics business focused on key sectors such as new energy, automotive and engineering projects to consolidate its niche advantages. In 2025, CIMC Wetrans ranked among the top five for three consecutive years in the “Comprehensive List of Freight Forwarding and Logistics Enterprises” published by the China International Logistics and Freight Forwarding Association.In the road transport vehicles business, during the Year, CIMC Vehicles recorded revenue of RMB 20.178 billion, representing a YoY decrease of 3.91%, and net profit of RMB 927 million, representing a YoY decrease of 14.29%. In the domestic market, the “Star-Chained Plan” reshaped the organisational and operational model, with revenue from the China semi-trailer business increasing by 14.65% YoY and gross profit margin increasing by 3.3%YoY. In overseas markets, the Global South markets maintained high-quality growth, with revenue reaching RMB 3.09 billion during the Reporting Period, representing a YoY increase of 17.7%, sales volume increasing by 29.1% YoY, and gross profit margin increasing by 1.3 percentage points YoY.The DTB business achieved steady growth in both sales volume and revenue, with a total of 28,570 units of mounted equipment products delivered, generating total revenue of RMB 3.184 billion, representing a YoY increase of 4.97%, with further improvement in market share of core products. Meanwhile, the Group continued to actively expand R&D and sales of new energy products, comprehensively building the EV-RT ecosystem and advancing the strategic development of pure electric tractors and trailers.In the airport facilities and logistics equipment/fire safety and rescue equipment, benefiting from the release and delivery of high-quality orders, the segment recorded revenue of RMB 7.619 billion during the Year, representing a YoY increase of 5.92%, and net profit of RMB 264 million. Airport equipment successfully delivered smart boarding bridges projects for Xi’an Xianyang International Airport, Antalya Airport in Türkiye and Lanzhou Airport, and secured major projects including Phase II of Nanning Airport and corridor projects at Hangzhou Airport T2 and T4 with its independently-developed innovative prefabricated fixed bridge solutions. Logistics equipment delivered automated three-dimensional warehouse systems for supporting the petrochemical and refining integration project in China. The fire safety and rescue equipment business advanced the overseas expansion of domestically manufactured products while focusing on frontier areas such as smart fire safety and unmanned fire trucks.2. In the Energy FieldIn the energy, chemical, and liquid food equipment business, the segment recorded revenue of RMB 27.192 billion, representing a YoY increase of 6.31%, and net profit increased significantly by 42.15% to RMB 1.040 billion. Among which, CIMC Enric recorded revenue of RMB 26.326 billion, representing a y YoY increase of 6.3%.Specifically, the clean energy segment advanced both offshore and onshore businesses, maintaining leading market share in key equipment such as high-pressure and cryogenic equipment, while capturing growth opportunities in natural gas applications in water and land transportation and power generation, and actively expanding into emerging markets for special industrial gas equipment in high-tech industries. In 2025, the segment secured new orders of RMB 22.229 billion, a record high. Among these, orders on hand for offshore clean energy-related business exceeded RMB 19 billion as of the end of 2025, with shipbuilding schedules extending to 2028. During the Year, the second coke oven gas comprehensive utilisation project — Linggang Phase I project — was successfully put into operation, and China’s first domestic mass-production bio-methanol (green methanol) project of CIMC Enric was completed and commenced operation. The chemical and environmental segment maintained its leading market share, while the medical equipment components and after-sales service businesses achieved steady growth. As of the end of 2025, orders on hand increased by 36.27% YoY to RMB 1.276 billion, providing strong support for future development. The liquid food segment maintained stable profitability, with gross profit margin increasing to 21.7% YoY.In the offshore engineering business, the Group’s core operating entity, CIMC Raffles, successfully achieved a strategic transformation from “manufacturing-led” to integrated “design + construction + integration” services, maintaining a leading position in the domestic market and emerging as an important new force in the international offshore engineering market. During the Reporting Period, the segment recorded revenue of RMB 17.938 billion, representing a YoY increase of 8.35%, and net profit of RMB 1.057 billion, becoming the Group’s second-largest profit contributor. Benefiting from the recovery of the global offshore engineering market, demand for high-end oil and gas equipment represented by FPSO/FLNG remained strong, while the industry accelerated its transition toward green and intelligent development, driving steady growth in new energy equipment orders. During the year, the Group secured new contract orders of US$1.20 billion, including 12+8 container feeder vessels, 2 offshore engineering special vessels and other module orders. As of the end of 2025, the accumulated value of orders on hand reached US$5.09 billion, with orders for oil & gas and special vessel accounting for approximately 70% and 30%, respectively. The Longkou base has scheduled production through to 2030.In the offshore engineering asset operation and management business, the Group continued to leverage its existing project experience and business capabilities, enhancing asset utilisation through its strong offshore platform operation and management capabilities. During the Reporting Period, the sixth-generation semi-submersible drilling platform “Deepsea Yantai” completed lease renewal, the ultra-deepwater semi-submersible drilling platform “Blue Whale No.1” signed a new lease with an international client, and the semi-submersible lifting/life platform “Blue Gretha (formerly Huadian CIMC 01)” also secured a new lease with an international client. Other platforms actively participated in market tenders to explore opportunities for asset disposal and leasing. During the Reporting Period, the average daily lease rate of semi-submersible and jack-up drilling platforms both recorded year-on-year increases.Future Development and ProspectsThe Group’s management stated, “The year 2026 marks the beginning of the ‘15th Five-Year Plan’. Starting from a newly upgraded brand identity, the Group will closely focus on ‘consolidating foundations, driving innovation, improving quality and efficiency’, and adopt a more proactive strategic approach to foster new opportunities and open new horizons amid complex changes, striving to build a ‘“becoming a high quality and trustworthy world-class multimodal transport enterprise.”About China International Marine Containers (Group) Co., Ltd.The CIMC Group is a world-leading equipment and solution provider in the logistics and energy industries, with its industry clusters mainly covering the logistics and energy fields, continuously strengthening its leading market position. In the logistics field, the Group continues to adhere to container manufacturing as its core business, based on which it has incubated the road transportation vehicles business and the airport facilities and logistics equipment / fire safety and rescue equipment business, supplemented by the logistics services business and recycled load business, providing products and services in the professional logistics field. In the energy field, the Group is principally engaged in the energy, chemical and liquid food equipment business and the offshore engineering business. Meanwhile, the Group continues to develop emerging industries and possesses financial and asset management businesses that serve the Group itself. As a diversified multinational industrial group serving the global market, CIMC has over 300 member enterprises across Asia, North America, Europe, and Australia, with a total of four listed companies, and customers and sales networks covering more than 100 countries and regions worldwide. In 2025, the Group recorded revenue of RMB 156.6 billion, ranking 154th on the 2025 Fortune 500 China list. The Group has maintained the world’s No.1 position for many consecutive years in core products such as standard dry containers, reefer containers, tank containers and semi-trailers. For more information, please visit http://www.cimc.com/. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Financial Highlights (Audited)(HKD Thousand)Year ended31 December20252024Revenue170,011271,372Gross Profit53,382104,720Profit Attributable to Owners of the Company13,68833,440Basic Earnings per Share (HK cents)0.972.37HONG KONG, Mar 26, 2026 - (ACN Newswire via SeaPRwire.com) - Dynasty Fine Wines Group Limited (“Dynasty” or “the Group”) (Stock Code: 00828), a premier grape winemaker in China, today announced its audited annual results for the year ended 31 December 2025 (“the Year”).In 2025, due to the impact of macroeconomy as well as weak demand in wine consumer market in the PRC, the Group’s sales of medium to high-end products significantly declined, resulting in a 37% year-on-year decrease in revenue to HK$170.0 million. In addition, due to the decline in sales revenue and gross margin, as well as an increase in loss allowances for trade receivables owing to extended repayment from certain distributors, the profit attributable to owners of the Company decreased by 59% year-on-year to approximately HK$13.7 million, although such decrease in profit was already partly offset by a net gain on compensatory surrender recognised during the year. Earnings per share of the Company was HK0.97 cents per Share.With strengthened marketing effort for dry white in coastal region and the launch of new white wine and sparkling wine products, sales of white wine products served as the Group’s primary revenue contributor. Sales of red and white wines products accounted for approximately 39% and 54% of the revenue respectively for the year (2024: approximately 41% and 56% respectively). The gross margin of red wine products and white wine products in 2025 were 25% and 35% respectively (2024: 36% and 41% respectively). The overall gross profit margin decreased to 31% in 2025 (2024: 39%), mainly due to change in product mix with more products with lower prices and margin in response to market dynamics and needs during the year.The Group has been actively pursuing innovation, embracing the “5+4+N” product strategy, with “N” standing for developing various customised products and continuously creating new products to meet the diverse needs of different Chinese consumer groups. During the year, the Group launched a new gift set product, i.e. Dynasty Chinese Zodiac Commemorative Dry Red Wine for the Yi Si Year of Snake, integrating with the Chinese zodiac culture and the leading rise of Chinese-style fashionable products, by presenting the zodiac culture in a youthful visual language to attract potential consumers. In addition, based on its existing high-quality products, the Group continues to introduce new products and promote product upgrades. The Group participated in the 112th China Food & Drinks Fair in March 2025, introducing new products such as Tianyang Tea-flavoured wine series, Dynasty Baifu VSOP brandy, etc., to further improve its product matrix and provide consumers with diverse consumption choices. Breaking through from the constraints of traditional wine, this tea-flavoured wine series, with its core concept of “tea and wine fusion,” has captured market attention with its unique craftsmanship. During the China Food & Drinks Fair, the Group also held wine-tasting events, where the new wines from Dynasty Ningxia Winery won industry praise for their unique flavor and exquisite craftsmanship. In the second half of the year, the Group also introduced new products “Hi” tea-flavoured wine series in response to the market need, which are very suitable for ready-to-drink scenarios among young consumers.In addition to enriching the product matrix, the Group has been closely cooperating with distributors, pressing ahead with its marketing campaign, accelerating the innovation of consumption scenarios, and enhancing and strengthening the wine cultural experience. The Group held its national tour tasting and business events, new products launch ceremonies at various exhibitions and wine fairs, as well as promotion activities for the 20th anniversary of listing in Hong Kong, during which the Group actively promoted its latest product mix that covered all product lines.During the year, two joint venture companies approved by the Group were established in February 2025, for the manufacturing and sales of yellow wine and Chenpi wine and trading of sauce-flavour baijiu products nationwide in the PRC respectively. For the yellow wine project, installation and testing of production equipment of a manufacturing plant with a tank capacity of 3,000 tonnes of yellow wine and special yellow wine – Chenpi wine in Jiangsu is expected to be completed in the second half of 2026. Upon completion of the project, the Group will be able to produce special yellow wine – Dongtai Chenpi Wine which allows the Group to effectively expand product categories, seize development opportunities in the Chinese yellow wine industry. The project expansion aims to effectively implement Dynasty’s strategic plan, further improving the industrial layout, expanding category tracks, tapping into industry potential, creating new performance growth points, and realising Dynasty Group’s transformation into a full category, full industry-chain enterprise. For the sauce-flavour baijiu segment, Dynasty sauce-flavour baijiu products, namely ‘Han’, ‘Tang’, ‘Song’ and ‘Ming’ have been newly launched in the core-market in Tianjin and Shanghai and will be further strategically promoted to other regions in 2026. The sauce-flavour baijiu products satisfy the needs of customer groups with different spending habits and contributing to the Group’s business. In the future, the continuous development and expansion of the sauce-flavour baijiu industry and the improvement of the level of customer groups will inevitably and effectively drive the increase in the sales scale of Dynasty wine and related products, thereby enhancing our industry influence and brand awareness.Regarding online sales, the e-commerce team of the Group comprehensively operates online stores itself on the traditional e-commerce platforms, such as JD.com, Tmall and Pinduoduo for product sales, as well as comprehensive innovation on its brand, product categories, and business systems, procedures and models via interest-based e-commerce platforms, including Rednote, Kuai and TikTok. The Group continues investing resources in a timely manner for improvement of the online sales channels and optimisation of online stores interface so as to capture the change of customer consumption behaviour in the PRC. The Group jointly develops exclusive products with leading e-commerce platforms, and promote AI livestreaming models in various channels to increase brand exposure and livestreaming sales, adopts big data analysis to accurately understand consumer demand, and injects strong momentum into the continued expansion of market scale. To establish an online brand matrix, the Group selected and authorised new online distributors during the year. The Group believes that the online platforms not only serve as business-to-customer trading platforms between the Group and the consumers, but also additional marketing and promotion channels for the brand, which can enhance the overall business potential of the Group.During the year, the Group had boasted brilliant results in major wine appraisal competitions. Among the numerous awards, “Dynasty Jin. Y Brandy XO barrel-aged 12 years” has won the Silver Award, at the 2025 International Wine & Spirit Competition (“IWSC”). The competition is considered the international standard for wine and spirits quality. Dynasty Baifu VSOP Brandy, Golden Dynasty Marselan Dry Red Wine, as well as Tianyang Tea Wine series are also awarded at the “2024 Qingzhuo Awards” in respective categories by China Alcoholic Beverages Association. “Dynasty Mengyuan White wine” has also won the Grand Gold Medal at the France International Wine Awards (“FIWA”) China region, Spring 2025 for its excellent quality. In addition, “Dynasty Inherit series – Dry Red Wine” has garnered the Gold Award at the same competition. These wines stood out from other entries for their elegant aroma, smooth body and round taste, and won the awards at the competitions, showing the charm and strengths of Dynasty wines to the country and the world. Dynasty has won the Silver Medal in the Sparkling Wine/China category, the Silver Medal in the Dry Wine/China category, and the Bronze Medal in the Medium/China category for its Dynasty Tianyang Winery Jasmine Sparkling Wine, Dynasty Inherit Series – Dry Red Wine, and Dynasty Inherit Series – Semi Dry White Wine, respectively, at the 2025 Cathay Global Wine & Spirits Awards Asia (“GWSAA”) (formerly known as the Cathay Hong Kong International Wine & Spirit Competition (“HKIWSC”)). This marks the 15th consecutive year that Dynasty products have won awards at the event, demonstrating industry-wide recognition of Dynasty’s exceptional winemaking skill and quality. In addition, “Dynasty Pinyue VSOP brandy” also won the Gold Medal in the brandy category of 2025 China Fine Wine Challenge.Mr. Wan Shoupeng, Chairman of Dynasty, concluded, “Looking ahead to 2026, the Group will continue to focus on market and consumer demand, reinvent consumption scenarios and promote product quality. At the same time, the Group will continue to innovate marketing strategies to stimulate brand vitality, further expand the market share of Dynasty’s products, strengthen Dynasty’s brand image as a representative of domestic wines, and set a benchmark for the Chinese wine industry, with the aim of bringing Dynasty’s superior wines to more consumers in the PRC. The Group will continue to uphold quality, seize the development trend of low-alcohol and younger consumer markets, and proactively develop new marketing prospects through innovation in products categories and consumption scenarios.”About Dynasty Fine Wines Group LimitedDynasty Fine Wines Group Limited was listed on the Main Board of The Stock Exchange of Hong Kong Limited with the stock code 00828 on 26 January 2005. Founded in 1980, Dynasty is the premier grape winemaker in China. It is principally engaged in the production and sale of grape wine products under its reputable “Dynasty” brand. Dynasty is the first Sino-foreign joint venture wine company in China with Tianjin Food Group Limited and the French grape wine giant, Remy Cointreau, as its current major shareholders. The Group produces and sells more than 100 grape wine product series, and introduces imported wine products, providing high-quality and value-for-money grape wines to the full range of consumer groups in China.For media enquiries:Strategic Financial Relations (China) LimitedMs. Anita Cheung Tel: 2864 4827Ms. Gianna Ye Tel: 2864 4837Ms. Hazel Ye Tel: 2864 4893Ms. Chloe Lyu Tel: 2864 4835Email: sprg-dynasty@sprg.com.hk Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Mar 26, 2026 - (ACN Newswire via SeaPRwire.com) - The Census and Statistics Department today released the latest external merchandise trade statistics. In February 2026, the total value of merchandise exports increased by 24.7% year-on-year to $408.8 billion. For the first two months of 2026, the total value of exports of goods amounted to $928.3 billion, marking an increase of 29.6% from the same period of last year.Hong Kong Trade Development Council’s Director of Research Bruce Pang said, over the past few months, Hong Kong’s external trade has continued to exhibit clear growth momentum. Although global geopolitical conditions remain tense, underlying demand from the Chinese Mainland and major overseas markets has remained resilient. We maintain a positive outlook, yet remain cautious in regard to Hong Kong’s trade performance.”HKTDC Media Room: https://mediaroom.hktdc.com/enMedia enquiriesPlease contact the HKTDC’s Communications & Public Affairs Department:Jane CheungTel: (852) 2584 4137Email: jane.mh.cheung@hktdc.org Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

NEW YORK, N.Y., Mar 26, 2026 - (ACN Newswire via SeaPRwire.com) - OpenClawd AI today released a security-focused platform update that adds automated skill vetting, verified installer sourcing, and runtime sandboxing to its managed OpenClaw hosting service. The update responds to two converging threats targeting users of the open-source AI agent formerly known as Clawdbot and Moltbot: a large-scale malware campaign inside the official OpenClaw skill marketplace, and a parallel wave of counterfeit installation packages being promoted through search engine results.The numbers are bad enough on their own. Together, they describe a supply chain that is actively hostile to casual users.One in Eight OpenClaw Skills Is Confirmed MaliciousIndependent security researchers recently completed an audit of the ClawHub skill marketplace — the primary distribution channel for third-party OpenClaw plugins. Out of 2,857 published skills, 341 were confirmed as malicious. That is approximately 12% of the entire marketplace.The findings include:Keyloggers and credential stealers deployed through skills that appear to offer legitimate productivity featuresSilent data exfiltration — one widely-downloaded skill was found to instruct the OpenClaw agent to execute curl commands that sent user data to an external server without any notification or consent promptPrompt injection payloads embedded in skill descriptions, designed to override the agent’s safety guidelines and force execution of unauthorized commandsPlaintext credential exposure — a separate audit found that over 280 additional skills were leaking API keys, tokens, and passwords in their source codeA major cybersecurity firm tested a specific ClawHub skill and published the results: nine security findings, including two critical and five high-severity issues. The skill functioned as what the researchers called “functionally malware.” The most widely-downloaded malicious skill on ClawHub was a cryptocurrency stealer.Fake OpenClaw Installers Are Being Promoted by Search EnginesThe marketplace problem is only half the story. A cybersecurity research team discovered that threat actors have published counterfeit OpenClaw installation packages on open-source code repositories. These fake installers mimic the legitimate OpenClaw setup process but instead deliver a malware packer that disables firewall protections and routes network traffic through compromised systems.The attack chain is straightforward: a user searches for “install OpenClaw” or “Clawdbot download.” An AI-powered search engine returns a result linking to the malicious repository. The user follows the instructions. The malware deploys silently.The researcher who discovered the campaign noted that the person who first reported the threat was a technical professional. “If a fellow IT pro is susceptible to this threat,” he said, “then anyone could be.”“There are now two ways to get compromised before you even run your first OpenClaw command,” said Danny Wilson, spokesperson for OpenClawd. “You can install a fake version of the software, or you can install the real version and then add a skill that steals your data. We built this update so that neither path exists on our platform.”What OpenClawd Ships TodayThis update targets both the supply chain and the runtime:Verified installer sourcing — all OpenClawd instances are provisioned from cryptographically signed OpenClaw releases, pulled directly from the official repository. No third-party install paths. No search engine intermediaries.Skill vetting pipeline — third-party skills go through automated static analysis and behavioral testing before activation. Skills flagged for network exfiltration, prompt injection patterns, or credential exposure are blocked by default.Runtime sandboxing — each skill executes in an isolated environment with explicit permission boundaries. A skill that requests network access to an unexpected endpoint triggers a review before execution.Credential isolation — API keys and tokens are stored in encrypted vaults and never exposed in plaintext to skill code or agent logsAutomatic CVE patching — hosted instances track the latest stable OpenClaw release (currently v2026.3.x), with all known vulnerabilities patched before deploymentOpenClawd does not operate its own skill marketplace. Skills available on hosted instances are drawn from the official ClawHub repository after passing the vetting pipeline described above.OpenClawd is not affiliated with the OpenClaw open-source foundation, OpenAI, Peter Steinberger, or any third-party security research firm cited in this release. It is an independent platform built on the open-source Clawdbot codebase. The open-source project remains free at github.com/openclaw/openclaw.Pricing starts with a free tier. Paid plans include dedicated compute, priority security patching, and uptime monitoring. Deploy a secure OpenClaw instance at https://openclawd.ai.Contact:Email: support@openclawd.ai Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com